New anti-obesity medications (AOMs), including semaglutide and tirzepatide, offer promising options for managing obesity and may be potential treatment options for obstructive sleep apnea
Semaglutide is a GLP-1 receptor agonist, which means it mimics the action of the glucagon-like peptide-1 hormone in the body
Decreased appetite is technically a side effect but also the primary mechanism through which weight loss occurs, so most people consider it a feature rather than a bug
Medicare analogues: self-administered drugs are in Part D, provider-administered in Part B
Kylee walks through what the evidence actually supports, and why you might be surprised
Now, PGRN is known to have an important role in lipid metabolism and insulin signaling